Everyone longs for normal. Normal may have changed, died, or been put off. But tomorrow morning, normal is waking up and looking to you for guidance

Sign up for RheumNow Live, March 20 and 21st. CME credits available. https://t.co/uwxOVh142F https://t.co/GqkCLBGl62

• https://bit.ly/3raRbVb

Download our latest resource--Televideo Joint Exam Checklist. https://t.co/XnyCW2eak8

• https://bit.ly/39oaWlY

The RheumNow podcast is now up--listen in on SoundCloud, RheumNow or Apple/Android car play. Rheumatology Burnout?--Dr. Cush reviews the top articles from the week of 1/29/21. https://t.co/HiX7qMFU6b https://t.co/KbaZ6XjHG6

• https://bit.ly/36ppUGu

Calculating Serious Infection Risk in IMID Patients Predictive modeling of data derived from the DANBIO registry (of treated IMID patients) revealed a 4 fold increased risk of serious infection in those starting biologic DMARD treatment. Read more: https://t.co/i2GwiCvCx6 https://t.co/9sZ79LyZ7u

• https://bit.ly/36IgXZd

High Placebo Responses in SLE Trials A systematic review in randomized controlled trials (RCTs) of non-renal, non-neuropsychiatric systemic lupus erythematosus (SLE) patients showing unexpectedly high placebo responses. Read more: https://t.co/zUPsVFEz4n https://t.co/Gk7ke4hBwY

• https://bit.ly/3am3tmC

QD Clinic Podcast for the week of Jan 29 - Pearls from Practice This wk: Arthritis &Crohn's Rhabdo or Not Dadgummit, Where's Waldos COVID Vaccine? "I Don't Know" A Tale of Two Gouts https://t.co/7ndYSOgh5R or listen on iTunes https://t.co/FHJv01AAbC https://t.co/780P7Bdw8F

• https://bit.ly/3qWe7HA
• https://bit.ly/2WXXRIy

RheumNow Podcast is up - Rheumatology Burnout (1.29.2021) - Vaccine #s, Colchicine in COVID, Rheums #2 in Burnout? Endometriosis & RA risk, Comorbidity as predictors. https://t.co/HiX7qMFU6b or listen on iTunes>>https://t.co/FHJv01AAbC or on SoundCloud>> https://t.co/0BfqGhxgQj https://t.co/j9nHMs4C6d

• https://bit.ly/36ppUGu
• https://bit.ly/2WXXRIy
• https://bit.ly/3otCg6H

Lupus Nephritis Despite Low Level Proteinuria https://t.co/awxvsvwGTg https://t.co/e6DV6sfiN5

• https://bit.ly/3t7OPrJ

2016 Deloitte report on top 10 healthcare innovations (Spot on!): 1 Next gen sequencing 2 3-D printing 3 AI 4 Immunotherapy 5 Point of care diagnostics 6 virtual reality 7 social media for Pts 8 Biosensors/trackers 9 Telehealth 10 Convenient care https://t.co/yWaqzM9pFC

• https://bit.ly/3iVF3EC

ACR Convergence 2020 Fireside Chats – Top presentations in nr-axSpA, AS, axial PsA Sponsored by Novartis Medical Affairs Unable to attend all the key sessions at #ACR20? Listen to the experts as they present their views on the top abstracts. https://t.co/r5Cf4WS63s https://t.co/NmDXrTPGXq

• https://bit.ly/2X5gOcI

Several studies have shown that Xray progression has lessened in recent yrs - presumeably from more aggressive Rx by Rheums! Still - Predictors of Xray long term damage = high ESR/CRP, baseline xray damage, -CCP/RF positivity https://t.co/2iaMiaquEV https://t.co/cgEP4QBvL4

• https://bit.ly/3cgTYIa
• https://bit.ly/3qYVlPR

JAK Inhibitor Misses Endpoint in Safety Study. Now What? Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class. https://t.co/EPVdAdPP37 https://t.co/Box5NaxsKV

• https://bit.ly/3iSl1Lc

News: #COVID19 risk may be reduced with #biologics and #JAKinhibitors, but increased with #glucocorticoids, Italian researchers report in @ArthritisRes https://t.co/zIef2aNCns

• COVID-19 risk not increased in rheumatic disease patients taking biologics, JAK…

SELECT-PsA2, UPA vs PLBO in refractory PsA, @ARD_BMJ Better ACR20 (57% vs 24% PLBO, NNT~3) and ACR50 (32% vs 5% PLBO, NNT~4). Decent PASI 90 (30% vs 6%, NNT~4) Similar adverse events to RA pop. Nice to have another option, esp in refractory dx! https://t.co/Zz2WYqswT2